Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00898833 · ClinicalTrials.gov registry record
Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583
A clinical trial, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- 868
- Enrollment target
NCT00898833 is a clinical trial that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 868 participants.
The verdict
NCT00898833 was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- 868 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is measuring plasma and urine biomarkers in patients with advanced prostate cancer that did not respond to hormone therapy.
Interventions
- OTHER laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 868 participants |
| Start Date | 2003-07 |
| Est. Completion | 2016-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00898833
The ClinicalTrials.gov registry entry for NCT00898833 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 868 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which laboratory biomarker analysis is the first listed.
NCT00898833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00898833 about?
NCT00898833 is a clinical study titled "Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583". RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is measuring plasma and uri...
What is the current status of trial NCT00898833?
This trial is currently terminated. The enrollment target is 868 participants. The study started on 2003-07. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00898833?
The interventions under investigation include: laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT00898833?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.